Last updated on April 19, 2014 at 13:20 EDT

Latest Oral Octreotide Stories

2012-06-26 10:24:10

Chiasma Developing Oral Alternative to Injectable Somatostatin Analogs; Phase 3 Trial Under Way HOUSTON, June 26, 2012 /PRNewswire-USNewswire/ -- Chiasma, a privately held biopharma company, today presented data at the annual meeting of The Endocrine Society (ENDO 2012) that show Octreolin, an investigational new oral drug being developed for use in acromegaly, reduced pituitary growth hormone secretion in healthy volunteers as effectively as shown in published studies of injectable...